In summary, in this study we have reported outcome data for consecutive glioblastomas patients treated with temozolomide and radiotherapy in a routine UK clinic and have shown that pyrosequencing is a robust and reliable assay for the determination of MGMT promoter methylation using diagnostic archival samples. Here, MGMT is linked to glioblastoma.